As part of our Wealth Creator Series , today we look at Lupin. This is one of the 39 stocks that were short-listed and passed through our stringent stock screen filters.
The company has significant market share in the fields of cardiovascular, diabetology, asthma, pediatrics and other similar therapy segments. In a bid to tap the vast patent expiries, Lupin plans to launch around 120 products in US over the next three years. These launches will be in the area of oral contraceptives, opthalmology, controlled release etc. It is also looking for larger acquisitions in Brazil, Mexico and Turkey.